Abstract
Many anti-viral agents have been tried in the treatment of chronic HBV infection (Pollard et al. 1978; Weller et al. 1982, 1983; Greenberg et al. 1976; Lok et al. 1984a; Smith et al. 1983). Only adenine arabinoside in both its native and monophosphate forms and the alpha interferons have been evaluated to a level where comments on clinical usefulness can be made.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abb J, Zachoval R, Einsenburg J, Pape GR, Zachoral ‘V, Deinhardt F (1985) Production of alpha interferon and interferon gamma by peripheral blood leukocytes from patients with chronic hepatitis B virus infection. J Med Virol 16: 171–176
Bassendine MF, Chadwick RG, Salmeron J, Shipton U, Thomas HC, Sherlok S (1981) Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology 80: 1016–1022
Eddleston AWLF, Mondelli M, Mieli-Vergani G, Williams R (1982) Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. Hepatology 2: 1225–1275
Friedman RL, Stark GR (1985) Interferon induced transcription of HLA and metallothione in genes containing homologous upstream sequence. Nature 314: 637–639
Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC (1976) Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295: 517–522
Hoofnagle JH, Hanson RG, Minuk GY, Pappas SC, Schafer DF, Dusheiko GM, Straus SE, Popper H, Jones AE (1984) Randomised controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86: 150–157
Hoofnagle JH, Hanson RG, Minuk GY, Pappas SC, Schafer DF, Dusheiko GM, Straus SE, Popper H, Jones AE (1984) Randomised controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86: 150–157
Iwarson S, Tabor E, Thomas HC, Snoy P, Gerety RJ (1985) Protection against hepatitis B virus infection by immunisation with hepatitis B core antigen. Gastroenterology 88: 763–767
Iwarson S, Thomas HC. Passive immunisation with anti-HBc in hepatitis B. (in preparation)
Kato Y, Nakagawa H, Kobayashi K, Hattori N, Hatano K (1982) Interferon production by peripheral lymphocytes in HBsAg-positive liver disease. Hepatology 2: 789–790
Levin S, Hahn T (1985) Interferon deficiency syndrome. Clin Exp Immunol 60: 267–273
Lok ASF, Wilson LA, Thomas HC (1984) Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J Antimicrob Chemother 14: 93–99
Lok ASF, Weller IVD, Karayannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC, Sherlok S (1984) Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 4: 45–49
Lok ASF, Weller IVD, Karayannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC, Sherlok S (1984) Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 4: 45–49
Novick DM, Lok ASF, Thomas HC (1984) Diminshed responsiveness of homosexual men to antiviral therapy for HBsAg positive chronic liver disease. J Hepatology 1: 29–35
Novick DM, Lok ASF, Thomas HC (1984) Diminshed responsiveness of homosexual men to antiviral therapy for HBsAg positive chronic liver disease. J Hepatology 1: 29–35
Perillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5’-monophosphate and prednisone withdrawal followed by adenine arabinoside 5 ’-monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780–786
Perillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5’-monophosphate and prednisone withdrawal followed by adenine arabinoside 5 ’-monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780–786
Perillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5’-monophosphate and prednisone withdrawal followed by adenine arabinoside 5 ’-monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88: 780–786
Pollard RB, Smith JL, Neal A, Gregory PB, Merigan TC, Robinson WS (1978) The effect of vidarabine on chronic hepatitis B infection. J Am Med Assoc 239: 1648–1650
Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A (1980) Seroconversion from hepatitis Be antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 79: 195–199
Regenstein FG, Roodman ST, Perillo RP (1983) Immunoregulatory T-cell subsets in chronic hepatitis B virus infection: The influence of homosexuality. Hepatology 31: 951–954
Sacks SL. Scullard GH, Pollard RB, Gregory PB, Robinson WS, Merigan TC (1982). Antiviral treatment of chronic hepatitis B virus infection: pharmokinetics and side effect of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother 21: 91–100
Schalm SW, Heijtink RA (1982) Spontaneous disappearance of viral replication and liver cell inflammation in HBsAg positive chronic active hepatitis: results of a placebo vs interferon trial. Hepatology 2: 791–794
Scullard GH, Pollard RB, Smith JL, Sacks SL. Gregory PB, Robinson WS, Merigan TC (1981) Antiviral treatment of chronic hepatitis B virus infection. 1. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 143: 772–783
Scully LJ, Shein R, Karayiannis P, Thomas HC. Lymphoblastoid interferon therapy of chronic hepatitis B virus infection: a randomised trial of 12 weeks vs 24 weeks of treatment (in preparation)
Smith CI, Weissberg J, Bernhardt L, Gregory PB, Robinson WS, Merigan TC (1983) Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. J Infect Dis 148: 907–913
Thomas HC, Shipton U, Montano L (1982) The HLA system: its relevance to the pathogenesis of liver disease. In: Popper H, Schaffner F (eds) Progress in liver disease, vol VI. Grune & Stratton, New York, pp 517–527
Thomas HC, Shipton U, Montano L (1982) The HLA system: its relevance to the pathogenesis of liver disease. In: Popper H, Schaffner F (eds) Progress in liver disease, vol VI. Grune & Stratton, New York, pp 517–527
Thomas HC, Lever AML, Scully LJ, Pignatelli M (1986) Approaches to the treatment of HBV and delta related liver disease. Semin Liver Dis 6: 34–41
Thomas HC, Pignatelli M, Lever AML (1986) Homology between HBV-DNA and a sequence of regulating the interferon antiviral system: a possible mechanism of persistent infection. J Med Virol 19: 63–69
Trepo C, Hantz O, Ouzan D, Chossegros P, Chevalier P, Berthillon P, Brette R (1984) Therapeutic efficacy of ARA-AMP in symptomatic HBeAg-positive CAH: a randomised placebo control study. Hepatology 4: 1055
Viola LA, Barrison IG, Coleman JC, Paradinas FJ, Fluker JL, Murray-Lyon IM (1981) Natural history of liver disease in chronic hepatitis B surface antigen carriers: a survey of 100 patients from Great Britain. Lancet 2: 1156–1159
Yokosuka O, Ornata M, Imazeki F, Hirota K, Mori J, Uchiumi K, Ito Y, Okuda K (1985) Combination of short term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study. Gastroenterology 89: 246–251
Weller IVD, Bassendine MF, Craxi A, Fowler MJF, Monjardino J, Thomas HC, Sherlock S (1982) Successful treatment of HBs and HBeAg-positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5’-monophosphate ( ARA-AMP ). Gut 23: 717–723
Weller IVD, Carreno V, Fowler MJF, Monjardino J, Makinen D, Varghese Z, Sweny P, Thomas HC, Sherlock S (1983) Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with IV bolus administration. J Antimicrob Chemother 11: 223–231
Weller IVD, Lok ASF, Mindel A, Karayiannis P, Sarah Galphin, Monjardino J, Sherlock S, Thomas HC (1985) A randomised controlled trial of adenine arabinoside 5’-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 26: 745–751
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Thomas, H.C., Scully, L.J., Lever, A.M.L., Yap, I., Pignatelli, M. (1986). A Review of the Efficacy of Adenine Arabinoside and Lymphoblastoid Interferon in the Royal Free Hospital Studies of Hepatitis B Virus Carrier Treatment: Identification of Factors Influencing Response Rates. In: Callea, F., Zorzi, M., Desmet, V.J. (eds) Viral Hepatitis. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71350-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-71350-7_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71352-1
Online ISBN: 978-3-642-71350-7
eBook Packages: Springer Book Archive